Home LiteratureArticle Details
PMID: 11556839 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

British journal of cancer ·Vol. 85 ·No. 6 ·2001-09-14 ·Pages 869-74

Wärnberg F, Nordgren H, Bergkvist L, Holmberg L

Abstract

Ductal breast carcinoma in situ (DCIS) is regarded as a precursor to invasive breast cancer. The progression from in situ to invasive cancer is however little understood. We compared some tumour markers in invasive and in situ breast carcinomas trying to find steps in this progression. We designed a semi-experimental setting and compared histopathological grading and tumour marker expression in pure DCIS (n = 194), small invasive lesions (n = 127) and lesions with both an invasive and in situ component (n = 305). Grading was done according to the Elston-Ellis and EORTC classification systems, respectively. Immunohistochemical staining was conducted for p53, c-erbB-2, Ki-67, ER, PR, bcl-2 and angiogenesis. All markers correlated with grade rather than with invasiveness. No marker was clearly associated with the progression from in situ to invasiveness. The expression of tumour markers was almost identical in the 2 components of mixed lesions. DCIS as a group showed a more 'malignant picture' than invasive cancer according to the markers, probably, due to a higher proportion of poorly differentiated lesions. The step between in situ and invasive cancer seems to occur independently of tumour grade. The results suggest that well-differentiated DCIS progress to well-differentiated invasive cancer and poorly differentiated DCIS progress to poorly differentiated invasive cancer.

MeSH Terms
Biomarkers, Tumor/analysis Breast Neoplasms/chemistry,pathology Carcinoma, Ductal, Breast/chemistry,pathology Carcinoma, Intraductal, Noninfiltrating/chemistry,pathology Cell Differentiation Disease Progression Female Gene Expression Regulation, Neoplastic Humans Immunoenzyme Techniques Ki-67 Antigen/analysis Neoplasm Invasiveness Neoplasm Staging Neovascularization, Pathologic/metabolism Proto-Oncogene Proteins c-bcl-2/analysis Receptor, ErbB-2/analysis Receptors, Estrogen/analysis Receptors, Progesterone/analysis Tumor Suppressor Protein p53/analysis
Chemicals
Biomarkers, Tumor Ki-67 Antigen Proto-Oncogene Proteins c-bcl-2 Receptors, Estrogen Receptors, Progesterone Tumor Suppressor Protein p53 Receptor, ErbB-2
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Wärnberg F
Department of Surgery, University Hospital Uppsala, S-751 85 Uppsala, Sweden.
Nordgren H
Bergkvist L
Holmberg L
References (21)
21 references, click to expand
  1. The clinical significance of pre-invasive breast carcinoma.
    Cancer. 1980 Aug 15;46(4 Suppl):919-25 PMID: 7397668
  2. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
    J Pathol. 1999 Mar;187(4):396-402 PMID: 10398097
  3. New aspects of the natural history of in situ and invasive carcinoma in the female breast. Results from autopsy investigations.
    Verh Dtsch Ges Pathol. 1985;69:88-95 PMID: 3006395
  4. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation.
    Radiology. 1989 Jul;172(1):235-41 PMID: 2544922
  5. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome.
    Am Surg. 1990 Jul;56(7):428-32 PMID: 2164336
  6. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.
    Br J Cancer. 1990 Jun;61(6):869-72 PMID: 2164835
  7. Breast conserving surgery in the management of in situ breast carcinoma.
    Eur J Surg Oncol. 1991 Jun;17(3):258-64 PMID: 1646128
  8. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
    J Clin Pathol. 1992 Jan;45(1):16-20 PMID: 1346789
  9. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Hum Pathol. 1992 Sep;23(9):974-9 PMID: 1355464
  10. Ductal carcinoma in situ.
    Cancer Invest. 1992;10(5):443-54 PMID: 1327429
  11. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.
    N Engl J Med. 1993 Jun 3;328(22):1581-6 PMID: 8292119
  12. Microvessel density and distribution in ductal carcinoma in situ of the breast.
    J Natl Cancer Inst. 1994 Apr 20;86(8):614-9 PMID: 7511693
  13. Ductal carcinoma in situ: a proposal for a new classification.
    Semin Diagn Pathol. 1994 Aug;11(3):167-80 PMID: 7831528
  14. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
    Cancer. 1995 Apr 15;75(8):2123-31 PMID: 7697603
  15. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.
    Breast Cancer Res Treat. 1995 Jun;34(3):253-63 PMID: 7579490
  16. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.
    J Pathol. 1995 Nov;177(3):275-83 PMID: 8551390
  17. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.
    J Clin Oncol. 1996 Mar;14(3):754-63 PMID: 8622021
  18. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma.
    Histopathology. 1996 Nov;29(5):397-409 PMID: 8951484
  19. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast.
    J Pathol. 1997 Feb;181(2):207-12 PMID: 9120727
  20. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ).
    Cancer. 1997 Nov 1;80(9):1740-5 PMID: 9351542
  21. Intraductal carcinoma of the breast: follow-up after biopsy only.
    Cancer. 1982 Feb 15;49(4):751-8 PMID: 6275978
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
2001-09-14
Pages
869-74
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2375068
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]